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Abstract
A specific response of human serum neutralizing antibodies (nAb) to a conformational epitope as a result of vaccination of
human subjects with the surface envelope glycoprotein (gp120) of HIV-1 has not previously been documented. Here, we
used computational analysis to assess the epitope-specific responses of human subjects, which were immunized with
recombinant gp120 immunogens in the VAX003 and VAX004 clinical trials. Our computational methodology—a variation of
sieve analysis—compares the occurrence of specific nAb targeted conformational 3D epitopes on viruses from infected
individuals who received vaccination to the occurrence of matched epitopes in the viruses infecting placebo subjects. We
specifically studied seven crystallographically defined nAb targeted conformational epitopes in the V3 loop, an
immunogenic region of gp120. Of the six epitopes present in the immunogens and targeted by known monoclonal
neutralizing antibodies, only the one targeted by the anti-V3 nAb 2219 exhibited a significant reduction in occurrence in
vaccinated subjects compared to the placebo group. This difference occurred only in the VAX003 Thailand cohort. No
difference was seen between vaccinated and placebo groups for the occurrence of an epitope that was not present in the
immunogen. Thus, it can be theorized that a specific 2219-like human neutralizing antibody immune response to AIDSVAX
immunization occurred in the VAX003 cohort, and that this response protected subjects from a narrow subset of HIV-1
viruses circulating in Thailand in the 1990s and bearing the conformational epitope targeted by the neutralizing antibody
2219.
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Introduction
In 1998 and 1999, two Phase III human clinical trials were
conducted by VaxGen (VaxGen Inc, South San Francisco, CA) to
test the efficacy of the AIDSVAX
TM HIV vaccine. The
AIDSVAX vaccine consisted of a bivalent immunogen derived
from the recombinant envelope glycoprotein gp120 of HIV-1
subtypes B and E (strains MN and A244) in VAX003, and
recombinant gp120 molecules from subtype B (strains MN and
GNE8) in VAX004 [1,2]. The choice of the HIV-1 strains was
made based on phylogenetic analysis to cover the majority of HIV
strains present in the regions where the clinical trials were
conducted [3–7]. In the VAX003 and VAX004 randomized
double-blind, placebo-controlled Phase III clinical trials, a total of
7963 volunteers were enrolled, and 611 of them were infected with
HIV-1 during the study [1,2]. The human subjects in the VAX003
and VAX004 trials thus represent existing, well-characterized
placebo-controlled vaccination research cohorts.
AIDSVAX vaccination failed to broadly protect the overall
study population (6.7% infection rate in the vaccinees, compared
to 7.0% in the placebo group, p.0.1), although certain subgroups
(non-Hispanic ethnic minorities, i.e. Asians and Africans) may
have experienced protection [1,2,8]. Protection, if it occurred, may
have correlated with higher titers of antibodies in those groups to
the matched viral strains, MN, GNE8, or A244, but the gp120
amino acid sequences of the infecting viruses were substantially
different from those in the immunogens [9], making the detection
of a protective effect by traditional means extremely difficult.
The third variable loop (V3 loop) of the HIV-1 surface envelope
glycoprotein (gp120) is an immunogenic region of the viral
envelope [10–12]. The V3 loop is known to contain epitopes that
induce both broadly and narrowly cross-reactive neutralizing
antibodies [12–16]. After the VAX004 clinical trial, only one
linear, one-dimensional (1D), sequence-defined V3 loop region
was evaluated as a putative antibody-targeted viral epitope – the
GPGRAF motif, presented in the V3 loop of the gp120’s from MN
and GNE8 strains. The presence of this sequence motif in infecting
viruses did not affect the degree of correlation between antibody
levels or HIV-1 incidence [1,9]. No crystal structure exists of a
monoclonal antibody specific for the entire GPGRAF sequence,
and a linear peptide like GPGRAF present in an immunogen may
give rise to many nAbs with diverse binding modes overlapping
within the GPGRAF peptide. Furthermore, the activities of nAbs
that engage epitopes not completely included in the GPGRAF
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the V3 loop crown were missed. Thus, the published study using
the GPGRAF fragment [9] was not truly epitope-specific and
could have detected only a fraction of the currently known V3
epitopes defined by 3D structures of V3-Ab crystallographic
complexes.
HIV vaccine-induced immune responses that are undetectable
by laboratory tests may be detected via ‘‘sieve’’ effects, wherein
HIV acquisition is partially blocked (only certain viruses matched
to the immune response are blocked). Prior attempts at HIV
vaccine trial sieve analysis have only focused on linear T-cell
epitopes, as defining conformational epitopes in linear DNA or
amino acid sequences presents a significant technical challenge to
traditional sieve analysis [17,18]. We attempted to meet this
challenge with a sieve analysis of the true conformational epitope-
specific human nAb response to immunization with the AIDS-
VAX vaccines using a novel computational structural biology
method for the detection of three-dimensionally (3D) -defined
conformational epitopes in gp120. The three-dimensional confor-
mational epitopes are projected into one-dimensional sequence
space via sensitive and specific ‘‘signature motifs’’ defined using a
panel of seven anti-V3 monoclonal antibodies’ crystal structures
[19,20]. Briefly, in this method, a conformational 3D-epitope is
defined by a number of sequentially-disparate but 3D space-
clustered amino acids positions (a sequence motif representing the
signature of the 3D conformational epitope: ‘‘signature motif’’).
The amino acids are restricted to those for which their side chains
are engaged in buried atomic contacts within the 3D molecular
surface of a monoclonal nAb in the crystallographic complex of
the nAb with its cognate bound viral peptide [19,20]. The
resolving of the 3D conformational epitope shape bound by the
specific monoclonal nAb into a simple sequence motif affords
rapid and accurate classification of any library of gp120 viral
sequences into those that contain the specific conformational 3D
epitope and those that do not.
In the present study, we report application of this methodology
in a novel form of sieve analysis [21], analyzing the library of
sequences of the viruses infecting vaccine and placebo recipients in
the VAX003 and VAX004 clinical trials (published by Global
Solutions for Infectious Diseases (GSID)). Specifically, we classified
the viruses infecting placebo and vaccinated patients into those
that contain certain conformational epitopes and those that do not
using the epitope motifs targeted by seven anti-V3-loop neutral-
izing monoclonal antibodies [20,22]. The exploratory metric used
was that one or more of the epitopes would show a lower rate of
occurrence in viruses infecting vaccinated subjects as compared to
viruses infecting placebo subjects, potentially indicating that the
vaccine imposed immune selection pressure that reduced the




The only human subjects’ data used in the current study were
blinded data on HIV-1 gp120 sequences, which are publicly
available through the GSID HIV Data Browser, therefore no IRB
approval is required.
Signature motifs for neutralization epitopes targeted by
nAbs
Signature motifs for the epitopes of seven broadly neutralizing
human monoclonal antibodies - 2219, 2557, 447-52D, 537-10D,
268-D, 3074 and 3791 [19,20] were used for this study. Each
signature motif targets an epitope in the V3 loop of gp120
(Figure 1).
Vaccine immunogens
The sequences of the V3 loops of the recombinant gp120s used
in AIDSVAX vaccines (Figure 1) were derived from GSID Data
Browser (GSID HIV Data Browser; URL: http://www.gsid.org/
gsid_hiv_data_browser.html; 9/2009).
Glycoprotein gp120 sequences of HIV-1 infected patients
All V3 sequences of infecting viruses were obtained from the
GSID Data Browser. A total of 382 volunteers were infected
during VAX004 and 229 volunteers were infected during
VAX003 Phase III clinical trials. 14 (VAX004) and 18
(VAX003) of the subjects had HIV-1 infection detected at month
0 and thus were excluded from future studies. For 32 volunteers
infected during VAX004 and 14 volunteers infected during
VAX003, no gp120 sequencing data are available. Therefore as
sequence-based epitope characterization could not be performed
on these subjects, they also were not included in the analysis.
Thus, in the current study viral sequences from 533 (336 from
VAX004, and 197 from VAX003) human subjects were
analyzed. In both trials the average number of days between
the estimated date of infection and the date of sample collection
for ‘placebo’ and ‘vaccine’ cohorts was nearly the same (in
VAX003: 128 days for ‘placebo’, 134 days for ‘vaccine’; in
VAX004: 108 days for ‘placebo’, 111 days for ‘vaccine’).
According to the trial protocol, at the evaluation time point in
VAX004 exactly 3 randomly selected clones were sequenced
from each infected volunteer. In VAX003 on average 3 randomly
selected clones per patient were sequenced (1 patient with 2
clones, 184 patients with 3 clones each, 8 patients with 4 clones
each, and 4 patients with 6 sequenced clones each). Importantly,
the average number of clones per patient in both ‘placebo’ and
‘vaccine’ cohorts of VAX003 was equal. In the current study we
considered a given human subject to be infected with an epitope-
decorated virus if at least one of the collected sequences contains
that epitope.
Epitope mapping and analysis
Mapping of specific neutralization epitopes in the viruses
infecting the study subjects was performed by searching the
sequences of each of the infecting viruses with each signature motif
listed in Figure 1. For the study, we asked the exploratory
question: could any of the nAbs elicited by AIDSVAX
immunization possibly protect against infection by the narrow
subset of viruses containing the nAb’s specific cognate signature
motifs? Specifically, the study was designed to address that
question by comparing the infection counts in vaccinated and
placebo groups (i.e. comparing the number of viruses infecting
vaccinees and containing signature motif ‘‘X’’ to the number of
viruses infecting placebo subjects containing the same signature
motif ‘‘X’’) with the expectation that the counts in the vaccinated
group would be lower than in the placebo group. P-values for each
comparison were estimated using a right-tailed Fisher Exact test
(or one-tailed hypergeometric test).
Results
The V3 loop signature motifs present in the vaccine
Signature motifs specific for the conformational epitopes
targeted by seven different anti-V3 loop neutralizing human
monoclonal antibodies were identified in our previous studies. The
presence of these motifs, and their associated conformational
AIDSVAX Epitope-Specific Response
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proteins used as immunogens during the AIDSVAX clinical trials
are shown in Figure 1. The subtype B HIV-1 strain MN, used in
both VAX003 and VAX004 clinical trials, contains six of the
conformational epitopes — those targeted by monoclonal
antibodies 268-D, 3074, 447-52D, 537-10D, 2219 and 2557.
The second subtype B HIV-1 gp120 from GNE8, which was
tested in the VAX004 clinical trial in North America and Europe,
contains only four of the seven conformational epitopes, those
targeted by monoclonal antibodies 268-D, 3074, 447-52D and
537-10D. The subtype E HIV-1 strain utilized in the AIDSVAX
vaccine during the VAX003 clinical trial in Thailand, A244, has
only one of seven conformational epitopes, that recognized by
monoclonal antibody 3074. None of these three protein
immunogens has the signature motif for the conformational
epitope targeted by monoclonal antibody 3791, so the infection
counts of viruses with this motif serves as an important internal
control: there should be no difference in counts between the two
groups since no response could have occurred to an epitope that
was not present in the immunogen.
The occurrence of signature motifs in sequences of
viruses recorded from the AIDSVAX trials
We constructed a dataset containing all the V3 loop sequences
of gp120s from the viruses listed in the GSID Data Browser (see
‘‘Materials and Methods’’) representing all of the viruses
identified to have infected the clinical trial subjects in VAX003
and VAX004. The dataset was divided into VAX003 and
VAX004 groups of study subjects. Each of these two groups was
separated into those who received vaccine and those who
received placebo injections. The counts of viruses with each of
the 7 signature motifs were recorded and compared as described
in the Methods section. Lower counts with a specific signature
motif in viruses infecting vaccinated subjects compared to the
counts with that same motif in viruses infecting placebo subjects
could be interpreted as evidence of the occurrence of a
conformational-epitope-specific immune antibody response in
vaccinees which prevented infection or after-infection outgrowth
of viruses bearing the conformational epitope represented by that
motif. The results of this comparison are summarized in the
Table 1. Notably, the count for viruses containing the 2219
signature motif was significantly (p=0.033) lower in the vaccinees
in the Thailand VAX003 cohort as compared to the count of
viruses containing the 2219 motif in the placebo group (Table 1).
The infection counts for the signature motif for the epitope
targeted by monoclonal antibody 2557 are only slightly different
from those for the motif 2219 (Table 1). However, as the 2557-
specific motif is a subset of that for 2219 (Figure 1), the results
for 2557 and 2219 might be interdependent. Thus, most likely,
observed reduction in the counts for the 2557-specific motif is just
an artifact conditioned by the similarity of the epitope targeted by
2557 to the epitope targeted by 2219. The infection counts for
viruses exhibiting other signature motifs were approximately
equivalent (accounting for the difference in sample size) in
vaccinees and placebo subjects. The infection counts for viruses
exhibiting the 3791 epitope, which was not present in the
immunogen, were also nearly identical between the vaccinees and
placebo subjects in both trials.
Figure 1. Library of signature motifs mapped to the V3 regions of AIDSVAX immunogens. Signature motifs recognized by each
monoclonal antibody are shown in the second column: the numbers indicate the recognized positions in the V3 loop and the letters indicate the
amino acid residues at each position required for recognition by that monoclonal antibody. Positions numbering is in the correspondence with the
standard V3 loop numbering described elsewhere [19,20]. Colored rectangles in the sequence column indicate the amino acid residues composing
the signature motif in each of the gp120s. Sequences without colored rectangles do not contain a given motif.
doi:10.1371/journal.pone.0027279.g001
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In previous studies [19,20], we identified seven overlapping
signature motifs specific for seven interspersed conformational
neutralization epitopes present in the V3 loop crown. These motifs
were defined as the critical residues recognized by various broadly
neutralizing human anti-V3 monoclonal antibodies, and allowed
us to identify the presence or absence of specific conformational
epitopes in any HIV-1 virus [19,20]. In the current study, we used
this novel capability to identify the presence or absence of these
epitopes in vaccine immunogens and in break-through viruses
infecting vaccine and placebo recipients in the VAX003 and
VAX004 Phase III clinical trials [1,2].
Given the specificity of the sequence motifs for neutralization
epitopes [19,20], and given also the internal negative control of the
3791-targeted neutralization epitope, which worked as expected,
we theorize that a protective neutralizing antibody response might
occur in VAX003 human subjects in Thailand to the epitope
recognized by monoclonal antibody 2219 as a result of
immunization with the AIDSVAX B/E immunogen. However,
it is likely that the hypothesized response was mediated by
polyclonal nAbs similar to 2219 and other nAbs (e.g. 2557, or not
tested in the study nAb), which have similar binding modes to
2219 and thus a similar signature motif as mAb 2219.
This finding is interesting in light of a previous study showing
that the effective neutralization potential of the 2219 antibody (i.e.
the cross-subtype breath after controlling for V3 epitope masking)
is the highest among tested V3-loop specific nAbs [20,22]. Anti-
variable loop antibodies have historically been viewed with
skepticism of their vaccine potential because the epitopes they
target are either easily escaped by frequent mutations (e.g. only a
narrow subset of viruses contains the epitope) or the epitopes, if
present, are masked by glycans or other variable loops (epitope
masking) [23]. Indeed, the prior study showed that different anti-
V3 antibodies have widely variable breadths of occurrence of their
targeted epitopes in circulating HIV viruses and widely variable
levels of masking of those epitopes when present [20,22]. One
might expect that the only anti-V3 loop nAbs that have a chance
of showing a protective effect in a clinical trial would be those that
have the widest breadth of occurrence of their targeted epitopes in
circulating viruses combined with the lowest level of masking of
that epitope. Indeed, the conformational epitope targeted by nAb
2219 was shown to be the least masked (i.e. most accessible for
nAbs) while occurring in 56% of circulating worldwide viruses,
therefore having the highest effective neutralization potential
among tested anti-V3 loop nAbs against circulating viruses [22].
If protection against the 2219-targeted conformational epitope
actually occurred in the Thai population, the lack of a difference in
the occurrence of the 2219 epitope between vaccine and placebo
in the North American cohort suggests one of the following
interpretations, or combinations thereof: a) that the AIDSVAX B/
E immunogen, which was used exclusively in VAX003, confers a
protective 2219 epitope-specific response, while AIDSVAX B/B,
used in North America, does not; b) that AIDSVAX B/E only
protects against viruses carrying the 2219 epitope in the
population of HIV viruses circulating in Thailand (mainly subtype
E) and not against the virus population infecting the US trial
population (predominantly clade B, with many having V3 loops
identical to the MN strain) [4,6,7]; c) that AIDSVAX B/E only
protects against viruses carrying the 2219 epitope in the setting of
non-sexual and/or heterosexual transmission, a possibly important
factor given that the HIV risk factors of the North American
cohort (MSM and heterosexual transmission) were indeed different
from the Thailand cohort (IVDU and heterosexual transmission);
or d) other undetermined host factors, such as differences in HLA
class II repertoire. Interestingly, only AIDSVAX B/E was used in
the recently successful RV144 HIV vaccine Phase III clinical trial
in the Thailand population using a prime-boost vaccine regimen
[24].
Although the overall VaxGen trial showed no broad protection,
this study detected a statistically significant reduction of counts of
the 2219-targeted conformational epitope in viruses infecting
vaccinees as compared to viruses infecting placebo recipients in a
randomized placebo-controlled blinded clinical trial. Although the
most obvious hypothetical explanation of such difference is that
vaccine-induced protection against viruses carrying the 2219-
targeted conformational epitope have occurred, this is only a
statistical result and other explanations are possible, including
undetected bias in the trial design. One possible way to address
that issue is to perform a follow-up experimental validation of the
2219-induced protection in uninfected Thai vaccinees. However,
this is a computational study intended to convey to the community
1) a novel sieve analysis method that addresses the challenge of
analyzing conformational antibody-targeted epitopes; and 2) a
potentially high-impact epidemiological result, which was previ-
Table 1. Screening for the signature motifs in datasets of gp120 sequences of HIV-1 strains infecting volunteers during AIDSVAX
Phase III clinical trials.
AIDSVAX Trial ID: VAX003 VAX004
Infection Status Viral sequence Placebo Vaccine p-value Placebo Vaccine p-value
Infected 268-D containing 1 2 0.879 33 105 1.000
Infected 447-52D containing 16 18 0.725 74 168 0.999
Infected 537-10D containing 9 12 0.828 64 142 0.986
Infected 2219 containing 23 12 0.033 85 156 0.588
Infected 2557 containing 21 13 0.099 75 153 0.936
Infected 3074 containing 84 82 0.488 103 181 0.275
Infected 3791 containing 9 9 0.606 1 1 0.584
Infected Unknown 6 8 n/a 8 24 n/a
Infected Total 105 106 n/a 127 241 n/a
Not Infected Total 1143 1155 n/a 1675 3346 n/a
doi:10.1371/journal.pone.0027279.t001
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powerful conformational epitope classification method [17,18]. It
is also important to note, that the purpose of the presented
statistical analysis was exploratory (hypothesis generation), not
statistical hypothesis testing. Therefore, no correction for multiple
testing was applied in order to avoid any false negative predictions.
In summary, in the present paper we describe a novel approach
for computational profiling of the human antibody response based
on counts in viral sequences of precisely defined signature motifs
that characterize the 3D conformational neutralization epitopes
targeted by specific anti-V3 neutralizing monoclonal antibodies.
The approach potentially identified, by inference, for the first time
a protective immune response to a specific HIV envelope
conformational antibody-targeted epitope as a result of immuni-
zation in humans. Thus, the current work suggests that
immunogens amplifying the elicitation of 2219-like (e.g., 2219 or
2557) antibodies might have potential value as HIV vaccine leads.
In addition, this type of analysis could be critical for the
interpretation of the data derived from prospective clinical trials
of vaccines designed to induce protective antibodies.
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